(Reuters) – AstraZeneca said on Monday its cancer treatment, Enhertu, developed with Japan’s Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients.
Enhertu met the main goal of a late-stage study testing the drug against a treatment pre-determined by physicians in people with HER2-positive metastatic breast cancer. The HER2 protein contributes to the growth and spread of breast cancer.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Vinay Dwivedi)
